Delving into the Latest Updates on TollB-001 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TollB 001, TollB-001, TollB001

Target

TLR8

Action

modulators

Mechanism

TLR8 modulators(Toll like receptor 8 modulators)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

Rheumatoid ArthritisScleroderma, Systemic

Inactive Indication-

Originator Organization

Toll Biotech Co.Ltd.(Beijing)

Active Organization

Toll Biotech Co.Ltd.(Beijing)

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

[Translation] A Phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of TollB-001 in healthy Chinese adult subjects, as well as to evaluate the food effect after a single oral dose of TollB-001

主要目的：评估中国健康成人受试者单次或多次口服TollB-001后的安全性和耐受性次要目的：评估中国健康成人受试者单次或多次口服TollB-001后的药代动力学（PK）特征评估食物对口服TollB-001的PK的影响探索性目的：评估中国健康成人受试者单次或多次口服TollB-001后的药效学（PD）特征

[Translation]

Primary objective: To evaluate the safety and tolerability of TollB-001 after single or multiple oral administration in healthy Chinese adult subjects Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of TollB-001 after single or multiple oral administration in healthy Chinese adult subjects To evaluate the effect of food on the PK of oral TollB-001 Exploratory objective: To evaluate the pharmacodynamic (PD) characteristics of TollB-001 after single or multiple oral administration in healthy Chinese adult subjects

Start Date27 Sep 2023

Sponsor / Collaborator

Toll Biotech Co.Ltd.(Beijing)

100 Clinical Results associated with TollB-001

Login to view more data

100 Translational Medicine associated with TollB-001

Login to view more data

100 Patents (Medical) associated with TollB-001

Login to view more data

100 Deals associated with TollB-001

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rheumatoid Arthritis	Phase 1	China	Toll Biotech Co.Ltd.(Beijing)	27 Sep 2023
Scleroderma, Systemic	IND Approval	China	Toll Biotech Co.Ltd.(Beijing)	31 Dec 2024